Furiex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda...
Friday, July 27, 2012, 4:18 PM ETFuriex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles